NeuroStar Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents With Depression
Neuronetics Will Acquire Greenbrook Through All-Stock Transaction; Interim Order Granted By Ontario Superior Court, Greenbrook Shareholders To Receive 0.01149 Neuronetics Shares Per Greenbrook Share, Ensuring 57% Ownership Of Combined Entity For...
Express News | Neuronetics and Greenbrook Tms Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
Press Release: Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
Greenbrook TMS Nears Acquisition by Neuronetics, Shareholders to Vote
NeuroStar Releases Software Upgrades to Elevate Patient Care
Retractable Technologies And 2 Other Penny Stocks Executives Are Buying
Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying
NeuroStar Marks Two Years of Transformative Impact With NeuroStar University
Insider Spends US$58k Buying More Shares In Neuronetics
Neuronetics Virtual Event to Discuss Greenbrook Merger Risks
Neuronetics, Inc. (NASDAQ:STIM) Just Reported, And Analysts Assigned A US$3.33 Price Target
Express News | JMP Securities Maintains Market Outperform on Neuronetics, Lowers Price Target to $3
Neuronetics Second Quarter 2024 Earnings: Misses Expectations
Neuronetics Outlines Future Plans and Merger Prospects
JMP Securities Maintains Neuronetics(STIM.US) With Buy Rating, Cuts Target Price to $3